Case Study

Universal Flu Vaccine Clinical Trial Case Study

Source: Health Decisions Inc.

Health Decisions used its Agile Clinical Development platform to provide near real-time safety data and complete enrollment on an accelerated schedule for a sponsor's M2e Universal Flu Vaccine candidate, which could potentially enable mass immunization against the full assortment of season and pandemic influenza A strains.

By using these adaptive enrollment strategies, Health Decisions has helped its sponsors enroll 85% of studies on time and 65% of studies early.

Study at a Glance:

  • Study Compound: Universal Flu Vaccine
  • Phase: II
  • Active Sites: 2, U.S.
  • Patients Enrolled: 80
  • Enrollment Period: 3 weeks
  • Patient Population: Healthy adults 19 - 49 years old